Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel

Journal of Controlled Release

Volumn 63, Issue 1-2, 2000, Pages 141-153

  Ceruti, Maurizio ^a   Crosasso, Paola ^a   Brusa, Paola ^a   Arpicco, Silvia ^a   Dosio, Franco ^a   Cattel, Luigi ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Liposomes; Paclitaxel prodrugs; Pharmacokinetics

Indexed keywords

ALCOHOL; CREMOPHOR; MACROGOL; PACLITAXEL; PACLITAXEL DERIVATIVE;

ARTICLE; BREAST CANCER; CONCENTRATION (PARAMETERS); CYTOTOXICITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHOLESTEROL; DRUG CARRIERS; DRUG STABILITY; FEMALE; HT29 CELLS; HUMANS; LIPOSOMES; MICE; MICE, INBRED BALB C; PACLITAXEL; PHOSPHOLIPIDS; PRODRUGS; SOLUBILITY; TUMOR CELLS, CULTURED; WATER;

EID: 0033978316     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(99)00198-4     Document Type: Article

References (49)

1. Wani M.C., Taylor H.L., Wall M.E., Coggon P., McPhail A.T. Plant antitumor agents: VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93:1971;2325-2327.
2. Schiff P.B., Frant J., Horwitz S.B. Promotion of microtubule assembly in vitro by Taxol. Nature. 277:1979;665-667.
3. Parness J., Horwitz S.B. Taxol binds to polymerized tubulin in vitro. J. Cell Biol. 91:1981;479-487.
4. Manfredi J.J., Parness J., Horwitz S.B. Taxol binds to cellular microtubules. J. Cell Biol. 94:1982;688-696.
5. Rowinsky E.K., Donehower R.C. Paclitaxel (Taxol). New Engl. J. Med. 332:1995;1004-1014.
6. Spencer C.M., Faulds D. Paclitaxel. Drugs. 48:1994;794-847.
7. Horwitz S.B. Mechanism of action of Taxol. Trends Pharmacol. Sci. 13:1992;134-136.
8. Fjallskog M.L., Frii L., Bergh J. Is Cremophor, solvent for paclitaxel, cytotoxic? Lancet. 342:1993;876.
9. Rowinsky E.K., Eisenhauer E.A., Chaudry V., Arbuck S.G., Donehower R.C. Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. 20:1993;1-15.
10. Dorr R.T. Pharmacology and toxicology of Cremophor EL diluent. Ann. Pharmacother. 28:1994;S11-S14.
11. Goldspiel B.R. Pharmaceutical issues: Preparation, administration, stability, and compatibility with other medications. Ann. Pharmacother. 28:1994;S23-S26.
12. Song D., Hsu L.F., Au J.L.S. Binding of Taxol to plastic glass container and protein under in vitro conditions. J. Pharm. Sci. 85:1996;29-31.
13. ®) in human cell lines. Cancer Chemother. Pharmacol. 33:1994;331-339.
14. Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.L., Trump D., Baker J.R., VanEcho D.A., VonHoff D.D., Leyland-Jones B. Hypersensitivity reactions from Taxol. J. Clin. Oncol. 8:1990;1263-1268.
15. Sharma U.S., Balasubramanian S.V., Straubinger R.M. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. J. Pharm. Sci. 84:1995;1223-1230.
16. Cserháti T., Holló J. Interaction of Taxol and other anticancer drugs with hydroxypropyl-β-cyclodextrin. Int. J. Pharm. 108:1994;69-75.
17. Cserháti T., Forgács E., Holló J. Interaction of Taxol and other anticancer drugs with α-cyclodextrin. J. Pharm. Biomed. Anal. 13:1995;533-541.
18. Sharma A., M Straubinger R. Novel Taxol formulations: Preparation and characterization of Taxol-containing liposomes. Pharm. Res. 11:1994;889-896.
19. Tarr B.D., Sambandan T.G., Yalkowsky S.H. A new parenteral emulsion for the administration of Taxol. Pharm. Res. 4:1987;162-165.
20. Burt H.M., Jackson J.K., Bains S.K., Liggins R.T., Oktaba A.M.C., Arsenault A.L., Hunter W.L. Controlled delivery of Taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid). Cancer Lett. 88:1995;73-79.
21. Ramaswamy M., Zhang X., Burt H.M., Wasan K.M. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J. Pharm. Sci. 86:1997;460-464.
22. Mellado W., Magri N.F., Kingston D.G.I., Garcia-Arenas R., Orr G.A., Horwitz S.B. Preparation and biological activity of Taxol acetates. Biochem. Biophys. Res. Commun. 124:1984;329-336.
23. Deutsch H.M., Glinski J.A., Hernandez M., Haugwitz R.D., Narayanan V.L., Suffness M., Zalkow L.H. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of Taxol with potent antitumor activity. J. Med. Chem. 32:1989;788-792.
24. Zhao Z., Kingston D.G.I. Modified Taxols. 6. Preparation of water-soluble prodrugs of Taxol. J. Nat. Prot. 54:1991;1607-1611.
25. Nicolaou K.C., Riemer C., Kerr M.A., Rideout D., Wrasidlo W. Design, synthesis and biological activity of protaxols. Nature. 364:1993;464-466.
26. Takahashi T., Tsukamoto H., Yamada H. Design and synthesis of a water-soluble Taxol analogue: Taxol-sialyl conjugate. Bioorg. Med. Chem. Lett. 8:1998;113-116.
27. Nicolaou K.C., Guy R.K., Pitsinos E.N., Wrasidlo W. A water-soluble prodrug of Taxol with self-assembling properties. Angew. Chem. Int. 33:1994;1583-1587.
28. Monfardini C., Veronese F.M. Stabilization of substances in circulation. Bioconjugate Chem. 9:1998;418-450.
29. Greenwald R.B., Gilbert C.W., Pendri A., Conover C.D., Xia J., Martinez A. Drug delivery systems: Water soluble Taxol 2′-poly(ethylene glycol) ester prodrugs - Design and in vivo effectiveness. J. Med. Chem. 39:1996;424-431.
30. Greenwald R.B., Pendri A., Bolikal D., Gilbert C.W. Highly water soluble Taxol derivatives: 2′-polyethylene glycol esters as potential prodrugs. Biorg. Med. Chem. Lett. 4:1994;2465-2470.
31. Dosio F., Brusa P., Crosasso P., Arpicco S., Cattel L. Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J. Control. Release. 47:1997;293-304.
32. Kim S. Liposomes as carriers of cancer chemotherapy: Current status and future prospects. Drugs. 46:1993;618-638.
33. Poste G. Liposomes targeting in vivo: Problems and opportunities. Biol. Cell. 47:1983;19-38.
34. Sharma A., Sharma U.S. Liposomes in drug delivery: Progress and limitations. Int. J. Pharm. 154:1997;123-140.
35. Gabizon A., Isacson R., Libson E., Kaufman B., Uziely B., Catane R., Ben-Dor C.G., Rabello E., Cass Y., Peretz T., Sulkes A., Chisin R., Berenholz Y. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol. 33:1994;779-786.
36. Sharma A., Mayhew E., Straubinger R.M. Antitumor effect of Taxol-containing liposomes in a Taxol-resistant murine tumor model. Cancer Res. 53:1993;5877-5881.
37. Balasubramanian S.V., Straubinger R.M. Taxol-lipid interactions: Taxol-dependent effects on the physical properties of model membranes. Biochem. 33:1994;8941-8947.
38. Sharma A., Sharma U.S., Straubinger R.M. Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. Cancer Lett. 107:1996;265-272.
39. Sharma A., Mayhew E., Bolcsak L., Cavanaugh C., Harmon P., Janoff A., Bernacki R.J. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer. 71:1997;103-107.
40. Riondel J., Jacrot M., Fessi H., Puisieux F., Potier P. Effects of free and liposome-encapsulated Taxol on two brain tumors xenografted into nude mice. In Vivo. 6:1992;23-28.
41. Crosasso P., Ceruti M., Brusa P., Arpicco S., Dosio F., Cattel L. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J. Control. Release. 63:2000;19-30.
42. Rouser G., Fleischer J., Yamamoto A. Two-dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 5:1970;494-496.
43. Maruyama K., Okuizumi S., Ishida O., Yamauchi H., Kikuchi H., Iwatsuru M. Phosphatidyl polyglycerols prolong liposome circulation in vivo. Int. J. Phar. 111:1994;103-107.
44. Crosasso P., Brusa P., Dosio F., Arpicco S., Cattel L. Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs. J. Pharm. Sci. 86:1997;832-839.
45. Brusa P., Dosio F., Pacchioni D., Delprino L., Grosa G., Bussolati G., Cattel L. Pharmacokinetics of an antibody-ricin conjugate administered intraperitoneally to mice. J. Pharm Sci. 83:1993;514-519.
46. Sparreboom A., van Tellingen O., Nooijen W.J., Beijen J.H. Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography. J. Chrom. B. 664:1995;383-391.
47. Saez R., Alonso A., Villena A., Goni F.M. Detergent like properties of polyethylene glycols in relation to model membranes. FEBS Lett. 137:1982;323-326.
48. Massemburg D., Lentz B.R. Poly(ethylene glycol)-induced fusion and rupture of dipalmitoylphosphatidylcholine large, unilamellar extruded vesicles. Biochemistry. 32:1993;9172-9180.
49. Bedu-Addo F.K., Huang L. Interaction of PEG-phospholipid conjugates with phospholipid: Implication in liposomal drug delivery. Adv. Drug Del. Rev. 16:1995;235-247.